Abeona Therapeutics Competitors

Cara Therapeutics (NASDAQ:CARA) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Volatility & Risk

Cara Therapeutics has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cara Therapeutics and Abeona Therapeutics, as reported by MarketBeat.com.

Cara Therapeutics currently has a consensus price target of $34.50, indicating a potential upside of 88.01%. Abeona Therapeutics has a consensus price target of $5.1667, indicating a potential upside of 113.50%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Cara Therapeutics.

Earnings & Valuation

This table compares Cara Therapeutics and Abeona Therapeutics' top-line revenue, earnings per share and valuation.

Abeona Therapeutics has lower revenue, but higher earnings than Cara Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cara Therapeutics and Abeona Therapeutics' net margins, return on equity and return on assets.

Insider and Institutional Ownership

67.0% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 36.5% of Abeona Therapeutics shares are owned by institutional investors. 5.7% of Cara Therapeutics shares are owned by company insiders. Comparatively, 19.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Abeona Therapeutics beats Cara Therapeutics on 10 of the 14 factors compared between the two stocks.

Protagonist Therapeutics (NASDAQ:PTGX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Volatility & Risk

Protagonist Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Protagonist Therapeutics and Abeona Therapeutics, as reported by MarketBeat.com.

Protagonist Therapeutics currently has a consensus price target of $36.25, indicating a potential upside of 53.80%. Abeona Therapeutics has a consensus price target of $5.1667, indicating a potential upside of 113.50%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Protagonist Therapeutics.

Earnings & Valuation

This table compares Protagonist Therapeutics and Abeona Therapeutics' top-line revenue, earnings per share and valuation.

Abeona Therapeutics has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Protagonist Therapeutics and Abeona Therapeutics' net margins, return on equity and return on assets.

Insider and Institutional Ownership

97.5% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 36.5% of Abeona Therapeutics shares are owned by institutional investors. 14.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 19.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Abeona Therapeutics beats Protagonist Therapeutics on 10 of the 14 factors compared between the two stocks.

Prothena (NASDAQ:PRTA) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Volatility & Risk

Prothena has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Insider and Institutional Ownership

90.2% of Prothena shares are owned by institutional investors. Comparatively, 36.5% of Abeona Therapeutics shares are owned by institutional investors. 30.4% of Prothena shares are owned by company insiders. Comparatively, 19.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Prothena and Abeona Therapeutics, as reported by MarketBeat.com.

Prothena currently has a consensus price target of $28.2857, indicating a potential upside of 26.73%. Abeona Therapeutics has a consensus price target of $5.1667, indicating a potential upside of 113.50%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Prothena.

Earnings & Valuation

This table compares Prothena and Abeona Therapeutics' top-line revenue, earnings per share and valuation.

Abeona Therapeutics has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prothena and Abeona Therapeutics' net margins, return on equity and return on assets.

Phibro Animal Health (NASDAQ:PAHC) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Volatility & Risk

Phibro Animal Health has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.

Insider & Institutional Ownership

50.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 36.5% of Abeona Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 19.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Phibro Animal Health and Abeona Therapeutics, as reported by MarketBeat.com.

Phibro Animal Health currently has a consensus target price of $21.50, indicating a potential downside of 0.32%. Abeona Therapeutics has a consensus target price of $5.1667, indicating a potential upside of 113.50%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Phibro Animal Health.

Valuation & Earnings

This table compares Phibro Animal Health and Abeona Therapeutics' top-line revenue, earnings per share and valuation.

Phibro Animal Health has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Phibro Animal Health and Abeona Therapeutics' net margins, return on equity and return on assets.

Summary

Phibro Animal Health beats Abeona Therapeutics on 9 of the 14 factors compared between the two stocks.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Volatility & Risk

Lexicon Pharmaceuticals has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.

Insider & Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.5% of Abeona Therapeutics shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 19.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Lexicon Pharmaceuticals and Abeona Therapeutics, as reported by MarketBeat.com.

Lexicon Pharmaceuticals currently has a consensus target price of $9.40, indicating a potential upside of 30.74%. Abeona Therapeutics has a consensus target price of $5.1667, indicating a potential upside of 113.50%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Lexicon Pharmaceuticals.

Valuation & Earnings

This table compares Lexicon Pharmaceuticals and Abeona Therapeutics' top-line revenue, earnings per share and valuation.

Lexicon Pharmaceuticals has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Abeona Therapeutics' net margins, return on equity and return on assets.

Summary

Abeona Therapeutics beats Lexicon Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

ESSA Pharma (NASDAQ:EPIX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Volatility & Risk

ESSA Pharma has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.

Insider & Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 36.5% of Abeona Therapeutics shares are owned by institutional investors. 19.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for ESSA Pharma and Abeona Therapeutics, as reported by MarketBeat.com.

ESSA Pharma currently has a consensus target price of $23.50, indicating a potential downside of 13.25%. Abeona Therapeutics has a consensus target price of $5.1667, indicating a potential upside of 113.50%. Given Abeona Therapeutics' higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than ESSA Pharma.

Valuation & Earnings

This table compares ESSA Pharma and Abeona Therapeutics' top-line revenue, earnings per share and valuation.

ESSA Pharma has higher earnings, but lower revenue than Abeona Therapeutics. ESSA Pharma is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ESSA Pharma and Abeona Therapeutics' net margins, return on equity and return on assets.

Summary

Abeona Therapeutics beats ESSA Pharma on 7 of the 12 factors compared between the two stocks.